AtriCure, Inc.
- Jurisdiction
United States - ISIN
US04963C2098 (ATRC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. Read full profile
Fundamentals
- Net revenue
€426.43M - Gross margin
74.7% - EBIT
-€29.06M - EBIT margin
-6.8% - Net income
-€31.01M - Net margin
-7.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| WEHRWEIN SVEN | N/A |
|
|
|
|
| WEHRWEIN SVEN | N/A |
|
|
|
|
| GROVES REGINA E | N/A |
|
|
|
|
| Doraiswamy Vinayak | Chief Scientific Officer |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | June 6, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | August 15, 2024 | $1.00K–$15.00K |
| Josh Gottheimer | July 9, 2024 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 1, 2024 (Q1 2024)